William Blair analyst Raju Prasad maintained a Buy rating on Bluebird Bio (NASDAQ: BLUE) today. The company’s shares closed on Friday at $150.
Prasad wrote:
“We Are in the Early Innings for Adoptive T-Cell Therapies, So What’s Next?”), the big question in the adoptive T-cell field at this point is how best to effectively target solid tumors given the data produced to date, which has underperformed that seen in liquid tumors (i.e., multiple myeloma). T argeting solid tumors brings with it specific challenges in recognition, specificity , and efficacy in a suppressive tumor microenvironment. From our discussions with key opinion leaders, we believe that finding highly expressed tumor antigens and avoiding T-cell exhaustion will remain pivotal to the success of cellular therapies in solid tumors.”
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 17.8% and a 59.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Audentes Therapeutics.
Bluebird Bio has an analyst consensus of Moderate Buy, with a price target consensus of $217.30, representing a 44.9% upside. In a report issued on August 2, Piper Jaffray also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $236.17 and a one-year low of $89.90. Currently, Bluebird Bio has an average volume of 882.6K.
Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.
